Suppr超能文献

对比增强光谱乳腺摄影术在新辅助化疗监测中的应用:与乳腺磁共振成像的比较。

Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.

机构信息

Radiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, Arcispedale Santa Maria Nuova - IRCCS, Viale Umberto I, No. 50, 42123, Reggio Emilia, Italy.

Radiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, AUSL Reggio Emilia, via Amendola 2, Reggio Emilia, 42122, Italy.

出版信息

Breast Cancer Res. 2017 Sep 11;19(1):106. doi: 10.1186/s13058-017-0899-1.

Abstract

BACKGROUND

Neoadjuvant-chemotherapy (NAC) is considered the standard treatment for locally advanced breast carcinomas. Accurate assessment of disease response is fundamental to increase the chances of successful breast-conserving surgery and to avoid local recurrence. The purpose of this study was to compare contrast-enhanced spectral mammography (CESM) and contrast-enhanced-MRI (MRI) in the evaluation of tumor response to NAC.

METHODS

This prospective study was approved by the institutional review board and written informed consent was obtained. Fifty-four consenting women with breast cancer and indication of NAC were consecutively enrolled between October 2012 and December 2014. Patients underwent both CESM and MRI before, during and after NAC. MRI was performed first, followed by CESM within 3 days. Response to therapy was evaluated for each patient, comparing the size of the residual lesion measured on CESM and MRI performed after NAC to the pathological response on surgical specimens (gold standard), independently of and blinded to the results of the other test. The agreement between measurements was evaluated using Lin's coefficient. The agreement between measurements using CESM and MRI was tested at each step of the study, before, during and after NAC. And last of all, the variation in the largest dimension of the tumor on CESM and MRI was assessed according to the parameters set in RECIST 1.1 criteria, focusing on pathological complete response (pCR).

RESULTS

A total of 46 patients (85%) completed the study. CESM predicted pCR better than MRI (Lin's coefficient 0.81 and 0.59, respectively). Both methods tend to underestimate the real extent of residual tumor (mean 4.1mm in CESM, 7.5mm in MRI). The agreement between measurements using CESM and MRI was 0.96, 0.94 and 0.76 before, during and after NAC respectively. The distinction between responders and non-responders with CESM and MRI was identical for 45/46 patients. In the assessment of CR, sensitivity and specificity were 100% and 84%, respectively, for CESM, and 87% and 60% for MRI.

CONCLUSION

CESM and MRI lesion size measurements were highly correlated. CESM seems at least as reliable as MRI in assessing the response to NAC, and may be an alternative if MRI is contraindicated or its availability is limited.

摘要

背景

新辅助化疗(NAC)被认为是局部晚期乳腺癌的标准治疗方法。准确评估疾病反应对于增加成功保乳手术的机会和避免局部复发至关重要。本研究的目的是比较对比增强光谱乳腺摄影(CESM)和对比增强磁共振成像(MRI)在评估肿瘤对 NAC 的反应中的作用。

方法

本前瞻性研究经机构审查委员会批准,并获得书面知情同意。2012 年 10 月至 2014 年 12 月期间,连续纳入 54 名有乳腺癌且需要 NAC 的同意患者。所有患者在 NAC 前、期间和后均接受 CESM 和 MRI 检查。MRI 首先进行,然后在 3 天内进行 CESM。根据 CESM 和 NAC 后病理检查结果(金标准),对每位患者的治疗反应进行评估,而不依赖于和不盲于其他检查结果。使用 Lin 系数评估测量值之间的一致性。在 NAC 前、期间和后,分别测试 CESM 和 MRI 测量值之间的一致性。最后,根据 RECIST 1.1 标准中设定的参数,评估 CESM 和 MRI 上肿瘤最大直径的变化,重点关注病理完全缓解(pCR)。

结果

共有 46 名患者(85%)完成了研究。CESM 预测 pCR 优于 MRI(Lin 系数分别为 0.81 和 0.59)。两种方法都倾向于低估残留肿瘤的实际范围(CESM 平均 4.1mm,MRI 平均 7.5mm)。在 NAC 前、期间和后,CESM 和 MRI 测量值之间的一致性分别为 0.96、0.94 和 0.76。CESM 和 MRI 可准确区分 46 例患者中的 45 例的反应者和非反应者。在评估 CR 时,CESM 的敏感性和特异性分别为 100%和 84%,MRI 的敏感性和特异性分别为 87%和 60%。

结论

CESM 和 MRI 病灶大小测量高度相关。CESM 在评估 NAC 反应方面似乎至少与 MRI 一样可靠,如果 MRI 禁忌或可用性有限,CESM 可能是一种替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dd4/5594558/bb9125d24294/13058_2017_899_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验